Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3

Exploratory analyses of PIONEER 3 (NCT02607865) assessed the efficacy (HbA1c change from baseline [BL], achievement of HbA < 7.0 %) of oral semaglutide (sema; 3, 7, or 14 mg), a novel oral GLP-1 receptor agonist, vs. sitagliptin (sita) 100 mg at week 26 by BL HbA1c and background OAD in pts with T2 D uncontrolled on metformin ± sulfonylurea. HbA was reduced across all BL HbA1a and OAD groups in all treatment arms; reductions were greater with higher BL HbA1c. HbA1c reductions were significantly greater with oral sema 7 and 14 mg vs. sita in all groups, except for 7 mg in the HbA1c ≤ 8.0 % group (Figure 1). Achievement of HbA1c < 7.0 % was greater with oral sema 7 and 14 mg vs. sita in all groups (Figure 2). In conclusion, oral sema 7 and 14 mg significantly improved glycaemic control vs. sita across most HbA1c groups, and irrespective of background OAD use.

Interessenskonflikt

Funding Novo Nordisk A / S

Disclosure J. Rosenstock: Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Genentech,

Inc., GlaxoSmithKline plc., Lexicon Pharmaceuticals, Inc., Melior Pharmaceuticals, Inc., Bukwang Pharm. Co.,

Ltd., Merck & Co., Inc., Oramed Pharmaceuticals, PegBio Co., Ltd., Pzer Inc. Other Relationship; Self;

Boehringer Ingelheim International GmbH, Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen

Pharmaceuticals, Inc., Novo Nordisk Inc., Sano. D.C. Allison: Advisory Panel; Self; Novo Nordisk Inc. Research

Support; Self; Bayer US, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Kowa

Pharmaceutical Europe Co. Ltd., Sano. A.L. Birkenfeld: None. T.M. Blicher: Employee; Self; Novo Nordisk A / S.

S. Deenadayalan: Employee; Self; Novo Nordisk A / S. Stock / Shareholder; Self; Novo Nordisk A / S. A. Kousholt:

Employee; Self; Novo Nordisk A / S. M.J. Davies: Advisory Panel; Self; Eli Lilly and Company, Janssen Global

Services, LLC., Novo Nordisk A / S, Sano-Aventis, Servier. Research Support; Self; Boehringer Ingelheim

International GmbH, Novo Nordisk Foundation. Speaker’s Bureau; Self; Boehringer Ingelheim International

GmbH, Eli Lilly and Company, Novo Nordisk A / S, Sano-Aventis, Takeda Pharmaceutical Company Limited.

Publication History

Article published online:
06 May 2021